MCID: OVR062
MIFTS: 34

Ovary Serous Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovary Serous Adenocarcinoma

MalaCards integrated aliases for Ovary Serous Adenocarcinoma:

Name: Ovary Serous Adenocarcinoma 12 15
Malignant Ovarian Serous Tumor 12 73
Serous Carcinoma of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5744
NCIt 50 C40025 C7550

Summaries for Ovary Serous Adenocarcinoma

Disease Ontology : 12 An ovary adenocarcinoma that derives from the lining of a cavity that produces a serum-like fluid (a serous cavity).

MalaCards based summary : Ovary Serous Adenocarcinoma, also known as malignant ovarian serous tumor, is related to ovarian serous cystadenocarcinoma and schimmelpenning-feuerstein-mims syndrome. An important gene associated with Ovary Serous Adenocarcinoma is HTRA3 (HtrA Serine Peptidase 3), and among its related pathways/superpathways are Cell surface interactions at the vascular wall and C-type lectin receptor signaling pathway. The drugs Gemcitabine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include ovary and t cells.

Related Diseases for Ovary Serous Adenocarcinoma

Diseases related to Ovary Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 ovarian serous cystadenocarcinoma 31.1 HRAS UBE4A USP2 ZNF217
2 schimmelpenning-feuerstein-mims syndrome 10.6 HRAS KRAS
3 periampullary adenoma 10.6 HRAS KRAS
4 paronychia 10.6 HRAS KRAS
5 bile duct cysts 10.6 HRAS KRAS
6 secondary hypertrophic osteoarthropathy 10.6 HRAS KRAS
7 nasal cavity adenocarcinoma 10.6 HRAS KRAS
8 anal canal adenocarcinoma 10.6 HRAS KRAS
9 ampulla of vater neoplasm 10.5 HRAS KRAS
10 lung adenoid cystic carcinoma 10.5 HRAS KRAS
11 nevus, epidermal 10.5 HRAS KRAS
12 villous adenoma 10.5 GNAS KRAS
13 acneiform dermatitis 10.5 HRAS KRAS
14 colloid carcinoma of the pancreas 10.5 HRAS KRAS
15 appendix cancer 10.5 GNAS KRAS
16 mixed cell type cancer 10.5 HRAS KRAS
17 adenosquamous cell lung carcinoma 10.4 HRAS KRAS
18 adenosquamous pancreas carcinoma 10.4 HRAS KRAS
19 core binding factor acute myeloid leukemia 10.4 HRAS KRAS
20 colonic benign neoplasm 10.4 CEACAM5 KRAS
21 biliary tract neoplasm 10.4 HRAS KRAS
22 duodenum cancer 10.3 HRAS KRAS
23 liver angiosarcoma 10.3 HRAS KRAS
24 pancreatic cystadenocarcinoma 10.3 CEACAM5 KRAS
25 lacrimal gland adenocarcinoma 10.3 HRAS KRAS
26 prostate squamous cell carcinoma 10.2 CEACAM5 HRAS
27 cecum adenocarcinoma 10.1 HRAS KRAS
28 sigmoid neoplasm 10.1 CEACAM5 HRAS KRAS
29 apocrine adenoma 10.1 CEACAM5 HRAS KRAS
30 aggressive digital papillary adenocarcinoma 10.0 CEACAM5 HRAS KRAS
31 biliary papillomatosis 10.0 CEACAM5 HRAS KRAS
32 bile duct adenocarcinoma 10.0 CEACAM5 HRAS KRAS
33 gastrointestinal system benign neoplasm 10.0 CEACAM5 HRAS KRAS
34 intestinal benign neoplasm 10.0 CEACAM5 HRAS KRAS
35 ovarian cancer 1 10.0 CEACAM5 HRAS KRAS
36 ovary epithelial cancer 10.0 CEACAM5 HRAS KRAS
37 colorectal adenocarcinoma 10.0 CEACAM5 HRAS KRAS
38 pulmonic stenosis 10.0 HRAS KRAS
39 female reproductive organ cancer 10.0 CEACAM5 HRAS KRAS
40 respiratory system cancer 10.0 CEACAM5 HRAS KRAS
41 rectal neoplasm 10.0 CEACAM5 HRAS KRAS
42 cell type cancer 10.0 CEACAM5 HRAS KRAS
43 gastrointestinal system cancer 10.0 CEACAM5 HRAS KRAS
44 pancreatic mucinous cystadenoma 10.0 CEACAM5 HRAS
45 endometrial stromal nodule 9.8
46 choriocarcinoma 9.8
47 costello syndrome 9.8 HRAS KRAS
48 ovary adenocarcinoma 9.7 CEACAM5 HRAS KRAS ZNF217
49 malignant ovarian surface epithelial-stromal neoplasm 9.6 CEACAM5 HRAS KRAS ZNF217
50 cell type benign neoplasm 9.6 CEACAM5 GNAS HRAS KRAS

Graphical network of the top 20 diseases related to Ovary Serous Adenocarcinoma:



Diseases related to Ovary Serous Adenocarcinoma

Symptoms & Phenotypes for Ovary Serous Adenocarcinoma

Drugs & Therapeutics for Ovary Serous Adenocarcinoma

Drugs for Ovary Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2 95058-81-4 60750
2
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
3
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
4
Iodine Approved, Investigational Phase 2 7553-56-2 807
5
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
6
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
7
Doxil Approved June 1999 Phase 2 31703
8 topoisomerase I inhibitors Phase 2
9 Albumin-Bound Paclitaxel Phase 2
10 Topoisomerase Inhibitors Phase 2
11 Anti-Bacterial Agents Phase 2
12 Antibiotics, Antitubercular Phase 2
13 Immunosuppressive Agents Phase 2,Phase 1
14 Anti-Infective Agents Phase 2,Phase 1
15 Antimetabolites Phase 2
16 Antiviral Agents Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 2
18 Antimitotic Agents Phase 2
19 Antineoplastic Agents, Phytogenic Phase 2
20 Respiratory System Agents Phase 2
21 N-monoacetylcystine Phase 2
22 Expectorants Phase 2
23 Antidotes Phase 2
24 Antioxidants Phase 2
25 Protective Agents Phase 2
26 cysteine Nutraceutical Phase 2
27 CHI3L1 protein, human

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
2 Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Terminated NCT02569957 Phase 2 Topotecan Hydrochloride;Topotecan Hydrochloride;Acetylcysteine
3 Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Withdrawn NCT02470559 Phase 1
4 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Ovary Serous Adenocarcinoma

Genetic Tests for Ovary Serous Adenocarcinoma

Anatomical Context for Ovary Serous Adenocarcinoma

MalaCards organs/tissues related to Ovary Serous Adenocarcinoma:

41
Ovary, T Cells

Publications for Ovary Serous Adenocarcinoma

Articles related to Ovary Serous Adenocarcinoma:

# Title Authors Year
1
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. ( 24577588 )
2014
2
Synchronous occurrence of endometrial stromal nodule with papillary serous carcinoma of ovary: report of a case and brief review of literature. ( 25404842 )
2014
3
Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival. ( 24427352 )
2014
4
Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment. ( 20707961 )
2010
5
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. ( 19798417 )
2009

Variations for Ovary Serous Adenocarcinoma

Cosmic variations for Ovary Serous Adenocarcinoma:

9
(show top 50) (show all 1230)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 8
2 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 8
3 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 8
4 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 8
5 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 8
6 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 8
7 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 8
8 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 8
9 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 8
10 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 8
11 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 8
12 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 8
13 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 8
14 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 8
15 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 8
16 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 8
17 COSM14065 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 8
18 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 8
19 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 8
20 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 8
21 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 8
22 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 7:55173971-55173971 8
23 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 8
24 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 8
25 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 8
26 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 8
27 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 7:55174769-55174769 8
28 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 7:55191808-55191808 8
29 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 8
30 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 8
31 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 7:55191730-55191730 8
32 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 8
33 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 8
34 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 8
35 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 8
36 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 8
37 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 8
38 COSM6904304 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 8
39 COSM159008 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 8
40 COSM6906506 ZFHX3 ovary,NS,carcinoma,serous carcinoma c.794A>C p.D265A 16:72959352-72959352 6
41 COSM6914646 YES1 ovary,NS,carcinoma,serous carcinoma c.194C>T p.S65F 18:756634-756634 6
42 COSM6969549 XRCC2 ovary,NS,carcinoma,serous carcinoma c.121G>C p.G41R 7:152660701-152660701 6
43 COSM6910241 XPO1 ovary,NS,carcinoma,serous carcinoma c.1072T>C p.S358P 2:61494067-61494067 6
44 COSM3446768 WT1 ovary,NS,carcinoma,serous carcinoma c.1285G>A p.D429N 11:32389123-32389123 6
45 COSM20660 WNK2 ovary,NS,carcinoma,serous carcinoma c.1486G>T p.V496L 9:93239962-93239962 6
46 COSM20717 WNK1 ovary,NS,carcinoma,serous carcinoma c.2829C>T p.Y943Y 12:880028-880028 6
47 COSM1035874 VHL ovary,NS,carcinoma,serous carcinoma c.430G>A p.G144R 3:10146603-10146603 6
48 COSM6923147 TSC2 ovary,NS,carcinoma,serous carcinoma c.4998C>A p.F1666L 16:2087871-2087871 6
49 COSM6975218 TSC2 ovary,NS,carcinoma,serous carcinoma c.1361+1G>A p.? 16:2062601-2062601 6
50 COSM6908724 TSC2 ovary,NS,carcinoma,serous carcinoma c.1217G>A p.R406K 16:2061968-2061968 6

Expression for Ovary Serous Adenocarcinoma

Search GEO for disease gene expression data for Ovary Serous Adenocarcinoma.

Pathways for Ovary Serous Adenocarcinoma

Pathways related to Ovary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.94 CEACAM5 HRAS KRAS
2
Show member pathways
11.89 CLEC4C HRAS KRAS
3
Show member pathways
11.85 GNAS HRAS KRAS
4
Show member pathways
11.72 GNAS HRAS KRAS
5 11.49 GNAS HRAS KRAS
6 11.09 HRAS KRAS
7 11.08 GNAS HRAS KRAS
8 11.02 HRAS KRAS
9 11.01 HRAS KRAS
10
Show member pathways
10.99 HRAS KRAS
11
Show member pathways
10.91 HRAS KRAS
12 10.79 HRAS KRAS
13 10.75 HRAS KRAS
14 10.62 HRAS KRAS
15 10.58 GNAS HRAS KRAS
16 10.27 HRAS KRAS

GO Terms for Ovary Serous Adenocarcinoma

Biological processes related to Ovary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.43 CEACAM5 HRAS KRAS
2 regulation of long-term neuronal synaptic plasticity GO:0048169 9.16 HRAS KRAS
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.13 CLEC4C HRAS KRAS
4 response to isolation stress GO:0035900 8.62 HRAS KRAS

Sources for Ovary Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....